| As Patients Pivot to Telehealth, Teladoc & Livongo Plan $18.5B Tie-Up | Frank Vinluan | 08/05/20 | New York |
| GentiBio Joins Cell Therapy Chase With $20M and New Treg Technology | Frank Vinluan | 08/05/20 | Boston |
| Bio Roundup: Cerevel’s Shell, Thrive’s Rise, Drug Price Drama & More | Frank Vinluan | 07/31/20 | National |
| Novartis Pays $75M to Get Hands on Sangamo’s Zinc Fingers for Drug R&D | Sarah de Crescenzo | 07/30/20 | San Francisco |
| Roche Pays $120M for Rights to UCB’s Tau-Targeting Alzheimer’s Drug | Frank Vinluan | 07/29/20 | Europe |
| Omega Therapeutics Lands $85M to Tap Into “Control Room” of Biology | Frank Vinluan | 07/29/20 | Boston |
| Forge Bio’s Combo Model for Gene Therapies Attracts $40M in Funding | Frank Vinluan | 07/21/20 | National |
| GSK Pays CureVac $328M in mRNA Vaccines Pact—Excluding COVID-19 | Frank Vinluan | 07/20/20 | Europe |
| Two Days, Six IPOs, and $1B Raised for Biotech Research & More | Frank Vinluan | 07/17/20 | National |
| Bio Roundup: Moderna Publishes, Life Science Cash, AdComm Votes & More | Frank Vinluan | 07/17/20 | National |
| Dewpoint, Merck Team Up to Tackle HIV Using Condensate Know-How | Sarah de Crescenzo | 07/15/20 | Boston |
| Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact | Frank Vinluan | 07/14/20 | Boston |
| Amgen Doubles Down on BeiGene Collaboration, Investing $421M More | Sarah de Crescenzo | 07/13/20 | San Francisco |
| NFlection Looks to Erase NF1 Tumors With Drug That Only Goes Skin Deep | Frank Vinluan | 07/09/20 | Philadelphia |
| Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases | Frank Vinluan | 07/06/20 | Boston |
| Amylyx Adds $30M to Press On With Neuro Drug for ALS, Alzheimer’s | Frank Vinluan | 07/01/20 | Boston |
| Chiesi Licenses Bioasis Tech to Tackle Brain Symptoms of Rare Diseases | Sarah de Crescenzo | 07/01/20 | Boston |
| La Jolla Pharma Steps In With Better Offer, Wins Tetraphase Bidding War | Frank Vinluan | 06/24/20 | San Diego |
| AsclepiX Emerges With $35M and an Eye Drug Challenger to Eylea, Lucentis | Frank Vinluan | 06/24/20 | National |
| Invitae Makes a Precision Oncology Push With $886M Deal for ArcherDx | Frank Vinluan | 06/22/20 | San Francisco |
| Shattuck Labs Nabs $118M for Cancer Drugs Like Keytruda, But Better | Frank Vinluan | 06/19/20 | Raleigh Durham |
| Bio Roundup: A Royal IPO, Akili Arrives, Orca Bio Surfaces & More | Frank Vinluan | 06/19/20 | National |
| Alpine Immune Sciences Lands AbbVie as R&D Partner for Lupus Drug | Frank Vinluan | 06/18/20 | Seattle |
| Orca Bio Surfaces With $192M and Recipes for “Custom” Cell Therapies | Frank Vinluan | 06/17/20 | San Francisco |
| Frazier Launches Lassen to Advance Antibodies Against Fibrosis, Cancer | Sarah de Crescenzo | 06/17/20 | San Diego |
| GSK Expands Synthetic Lethality Scope With $120M Ideaya Bio Alliance | Frank Vinluan | 06/16/20 | San Francisco |
| Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More | Sarah de Crescenzo | 06/12/20 | National |
| Novo Nordisk Strikes a $725M Deal for AstraZeneca Spinout Corvidia | Frank Vinluan | 06/11/20 | Boston |
| Verve Therapeutics Adds $63M to Edit Heart Attack Risk Out of Genes | Frank Vinluan | 06/11/20 | Boston |
| Melinta Expands Antibiotics Lineup With $39M Tetraphase Acquisition | Frank Vinluan | 06/09/20 | New York |
